On November 9, 2018, MediRätt announced that the company had called upon a second tranche of convertibles under the agreement on financing through issuance of convertibles entered into with European Select Growth Opportunities Fund (the "Investor"). MediRätt also informed that the company had decided to, at no consideration, issue 430,851 warrants TO6 to the Investor and 426,692 warrants to iZafe AB (formerly Sensec Personlig Säkerhet AB, currently under name change) with the right and obligation to transfer its warrants at no consideration to the shareholders in MediRätt pro rata in proportion to the number of shares in MediRätt they hold at the date five trading days after the date of registration of the issue resolution at the Swedish Companies Registration Office.
The shareholders of MediRätt AB, 556762-3391, (the "Company") are hereby invited to an Extraordinary General Meeting on Tuesday, 18 December 2018 at 14.00, at Priority, Skeppsbron 24, Stockholm, Sweden.
On May 21, 2018, MediRätt and European Select Growth Opportunities Fund (the "Investor") signed an agreement under which MediRätt may issue convertible bonds in several tranches for a total maximum amount of SEK 50 million over 18 months. A first tranche of SEK 2.5 million has been issued on June 13, under which all the convertibles have been converted into shares as of today, strengthening the company's equity.
THIRD QUARTER IN BRIEF
2,704 SEK 000s (0 SEK 000s)
PROFIT AFTER TAX:
-2,101 SEK 000s (-1,100 SEK 000s)
PROFIT PER SHARE BEFORE DILLUTION:
-0.2 SEK (-0.1 SEK)
NUMBER OF SHARES AS AT 30 JUNE:
MediRätt and European Select Growth Opportunities Fund (the "Investor") have signed an agreement under which MediRätt may issue convertible bonds (the "Convertibles") in several tranches for a total maximum amount of SEK 50 million over 18 months. The capital injection will be used for the development and launch of the digital drug dispensing machine Dosell. In connection with the issuance of Convertibles, MediRätt will also issue warrants (the "Warrants") to the Investor as well as to existing shareholders as an anti-dilution measure. The Warrants will be issued free of charge.
2017 IN BRIEF
154 802 SEK (-- SEK)
RESULTS AFTER TAX:
-4 268 476 SEK (-6 575 096 SEK)
RESULT PER SHARE AFTER DILUTION:
-0,36 SEK (-0,60 SEK)
NUMBER OF SHARES PER 31 DEC:
11 917 028 (10 672 028)
On April 11, MediRätt's Annual General Meeting will be held. Prior to this, two new experienced regular members are proposed to join the Board; Helena Gille, former business manager for Apodos operations at Apoteket AB, and Viveca Gyberg, TV profile, doctor and researcher at the Department of Medicine at Karolinska Hospital in Solna.
The shareholders of MediRätt AB, 556762-3391 (the "Company") are hereby invited to the Annual General Meeting on Wednesday, 11 April 2018 at 2:00 p.m. at Priority, Skeppsbron 24, Stockholm, Sweden.
On Friday, January 19, MediRätt announced that the cooperation with Apoteket AB was terminated. With the majority of questions received from shareholders, MediRätt's CEO Carl Johan Merner today chooses to clarify information regarding the background of the cooperation, what it means to MediRätt and its shareholders and plans in the future.
Pressmeddelanden och rapporter via E-post.